UPS
64
3
SRE
54
7
EXC
64
3
AAP
30
2
NFLX
51
3
KIM
50
3
PX
56
3
CTAS
68
9
GT
49
2
QRVO
20
-9
EBAY
29
2
T
41
2
COP
51
3
AON
49
2
CHK
55
-2
PVH
45
-4
F
47
5
CRM
59
2
URI
68
3
EIX
53
2
UPS
64
3
SRE
54
7
EXC
64
3
AAP
30
2
NFLX
51
3
KIM
50
3
PX
56
3
CTAS
68
9
GT
49
2
QRVO
20
-9
EBAY
29
2
T
41
2
COP
51
3
AON
49
2
CHK
55
-2
PVH
45
-4
F
47
5
CRM
59
2
URI
68
3
EIX
53
2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

97% Accuracy For The Last 8 Years... Really?

Click HERE to see it with your own eyes.
Sell
49

KROS
Keros Therapeutics

Last Price:
42.08
Seasonality Move:
-32.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Here's Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)

And you can click here to get his three top picks to get started right now

Keros Therapeutics Price Quote

$42.08
-1.41 (-3.24%)
(Updated: March 30, 2023 at 10:00 PM ET)

Keros Therapeutics Key Stats

Sell
49
Keros Therapeutics (KROS) is a Sell
Day range:
$42.10 - $44.32
52-week range:
$24.38 - $68.29
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
4.47%
Volume:
165K
Avg. volume:
256.1K
1-year change:
-21.06%
Market cap:
$1.2B
Revenue:
$0
EPS:
$-4.15

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$70.1M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $120.3M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1.2M

Keros Therapeutics Return On Invested Capital

Data Unavailable

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Ampio Pharmaceuticals Inc (AMPE)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 1.27%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 96.67
Upside from Last Price: 122.27%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    30.3M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    368.2K KROS shares are owned by insiders